Pulmonary hypertension; aetio-pathogenesis, current treatment and future prospects

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Biomedical and Pharmaceutical Research

• Publication date

  2017-08-30

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives

  2017cited by this paper
• The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease

  2017cited by this paper
• Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension.

  2015cited by this paper
• Oral l-citrulline malate in patients with idiopathic pulmonary arterial hypertension and Eisenmenger Syndrome: a clinical trial.

  2014cited by this paper
• Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.

  2014cited by this paper
• The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension.

  2014cited by this paper
• Role of atrial natriuretic peptide in mediating the blood pressure-independent natriuresis elicited by systemic inhibition of nitric oxide

  2014cited by this paper
• Iron deficiency in patients with idiopathic pulmonary arterial hypertension.

  2014cited by this paper
• The Fifth World Symposium on Pulmonary Hypertension.

  2013cited by this paper
• Riociguat for the treatment of pulmonary arterial hypertension.

  2013cited by this paper
• FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.

  2013cited by this paper
• EXPERIMENTAL EVALUATION OF THE EFFECT OF ENDOTHELIN RECEPTOR ANTAGONIST ON NATTOKINASE INDUCED CHANGE IN HEART RATE AND BIOCHEMICAL PARAMETERS IN THE RAT

  2013cited by this paper
• Definitions and diagnosis of pulmonary hypertension.

  2013cited by this paper
• Plasma Endothelin-1 and Vascular Endothelial Growth Factor Levels and Their Relationship to Hemodynamics in Idiopathic Pulmonary Fibrosis

  2012cited by this paper
• Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension

  2011cited by this paper
• Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target

  2011cited by this paper
• Oxygen sensing, homeostasis, and disease.

  2011cited by this paper
• Association of anemia and long-term survival in patients with pulmonary hypertension.

  2011cited by this paper
• Iron deficiency: an ominous sign in patients with systolic chronic heart failure.

  2010cited by this paper
• Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

  2010cited by this paper
• Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies

  2010cited by this paper
• Iron deficiency is common in idiopathic pulmonary arterial hypertension

  2010cited by this paper
• Updated clinical classification of pulmonary hypertension.

  2009cited by this paper
• Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.

  2008cited by this paper
• Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling

  2008cited by this paper
• The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted

  2007cited by this paper
• Pathology of pulmonary hypertension.

  2007cited by this paper
• Oxygen Homeostasis

  2005cited by this paper
• Imatinib for the treatment of pulmonary arterial hypertension.

  2005influential reference
• Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women.

  2004cited by this paper
• Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction.

  2001cited by this paper
• Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A.

  1999cited by this paper
• Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression.

  1998cited by this paper
• Determination of aminopeptidase X activity in tissues of normo- and hypertensive rats by capillary electrophoresis.

  1997cited by this paper
• Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes.

  1997cited by this paper
• Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells.

  1996cited by this paper
• Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop.

  1994cited by this paper
• Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis.

  1993cited by this paper
• Integrative Physiology/experimental Medicine Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension Materials and Methods Mct Treatment, Inhibitor Treatment, and Hemodynamic Measurements Assessment of Vascular Remodeling and Proliferation in Situ Cell Culture Proliferation Assays Chemot

  year unknowncited by this paper

• No citing papers are available for this paper.